肾移植受者同服钙剂不影响免疫抑制药物剂量
结果显示霉酚酸AUC0-12比值为0.94(90%CI 0.83-1.07),他克莫司AUC0-12比值为1.00(90%CI 0.92-1.09),无临床相关药代动力学药物相互作用,提示无需错时给药。
要点
- 钙/维生素D与吗替麦考酚酯同服不引起临床相关药代动力学相互作用
- 钙/维生素D与他克莫司同服无临床相关药代动力学相互作用
- 基于该研究,无需推荐钙剂与免疫抑制药物错时2-3小时给药
核心结论
- 肾移植受者同服钙/维生素D补充剂与吗替麦考酚酯和他克莫司无临床相关药代动力学药物相互作用。
- 基于上述观察,推荐钙剂与免疫抑制药物错时给药似乎没有必要。
研究设计与样本
- 每例受者接受两次12小时药代动力学评估,分别在有和无钙/维生素D补充剂条件下同时测定霉酚酸和他克莫司浓度。
- 采用体积吸收微采样(VAMS)采集毛细血管血样。
- 依据EMA生物等效性指南,通过有/无钙剂条件下AUC0-12和Cmax的比值评估临床相关相互作用。
主要发现
- 霉酚酸AUC0-12比值为0.94(90%CI 0.83-1.07),Cmax比值为0.79(90%CI 0.65-0.97)。
- 他克莫司AUC0-12比值为1.00(90%CI 0.92-1.09),Cmax比值为0.96(90%CI 0.87-1.07)。
关键数值与推荐
- 霉酚酸AUC0-12比值0.94(90%CI 0.83-1.07),Cmax比值0.79(90%CI 0.65-0.97)。
- 他克莫司AUC0-12比值1.00(90%CI 0.92-1.09),Cmax比值0.96(90%CI 0.87-1.07)。
- EMA生物等效性指南用于判定临床相关相互作用。
临床怎么用
- 肾移植受者同服钙/维生素D补充剂时,无需因药代动力学相互作用而调整吗替麦考酚酯或他克莫司剂量。
- 无需对钙剂与吗替麦考酚酯或他克莫司实施错时给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy following kidney transplantation entails a risk of both drug-drug interactions (DDIs) and reduced patient adherence. Co-administration of calcium supplementation and mycophenolate mofetil (MMF) has previously been shown to influence pharmacokinetics (PK) of MMF. In current DDI databases, there is a recommendation for 2- to 3-h time-shifted administration. Whether a similar interaction potentially exists for tacrolimus has not been evaluated. We aimed to investigate the potential PK DDI between co-administrated calcium/vitamin D supplementation and the immunosuppressive drugs MMF and tacrolimus, using volumetric absorptive microsampling (VAMS). METHODS: Twenty-five kidney transplant recipients on stable MMF, tacrolimus and prednisolone treatment provided two 12-h PK investigations of simultaneous assessment of both mycophenolic acid (MPA) and tacrolimus concentrations. One PK investigation with and one without concomitant treatment with a calcium/vitamin D supplement. Capillary blood samples using VAMS were utilized to obtain samples in a patient friendly manner. Clinically relevant interactions were assessed by the with/without ratio of AUC0-12 and Cmax in accordance with EMA bioequivalence guidelines. RESULTS: The MPA AUC0-12 ratio was 0.94 (90% confidence interval [CI], 0.83-1.07) and the Cmax ratio was 0.79 (90% CI, 0.65-0.97). For tacrolimus, the AUC0-12 and Cmax ratios were 1.00 (90% CI, 0.92-1.09) and 0.96 (90% CI, 0.87-1.07), respectively. CONCLUSION: In kidney transplant recipients there is no clinically relevant PK DDI caused by concomitant administration of calcium/vitamin D supplementation with MMF and tacrolimus. Based on these observations, recommendation of time-shifted administration of calcium supplements and immunosuppressive drugs seems unnecessary.
引用
- Aftret LH, Ellingsen AØ, Midtvedt K, et al. Concomitant calcium supplementation does not compromise immunosuppressive dosing in kidney transplant recipients. Br J Clin Pharmacol. 2026. PMID: 42963953. doi:10.1002/bcp.70905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。